List of Excipients in Branded Drug EFFIENT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	CELLULOSE, MICROCRYSTALLINE
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	FERRIC OXIDE YELLOW
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	GLYCERYL DIBEHENATE
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	HYPROMELLOSE
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	HYPROMELLOSE 2910
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	LACTOSE MONOHYDRATE
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE

Effient Excipient Strategy and Commercial Opportunities for Prasugrel

Last updated: August 9, 2026

Effient is the branded prasugrel hydrochloride tablet developed by Daiichi Sankyo and Eli Lilly for reducing thrombotic cardiovascular events in patients with acute coronary syndrome managed with percutaneous coronary intervention. Its excipient platform is conventional: lactose anhydrous, microcrystalline cellulose, crospovidone, hypromellose and magnesium stearate, with a film coat containing standard polymeric, mineral and iron-oxide components.[1]

The commercial opportunity is not based on a complex delivery system. It is based on manufacturing efficiency, reliable low-dose content uniformity, differentiated excipient profiles, hospital packaging, alternative dosage forms and global generic or 505(b)(2) development. The core tablet formulation is comparatively accessible, but prasugrel products must meet demanding quality and clinical-use requirements because the drug is an antiplatelet agent with clinically important bleeding risks.

What excipients are used in Effient tablets?

Effient uses a conventional immediate-release compressed-tablet formulation. The FDA prescribing information identifies the following inactive ingredients:[1]

Excipient	Likely function in Effient
Lactose anhydrous	Diluent and tablet-mass builder
Microcrystalline cellulose	Diluent, dry binder and compression aid
Crospovidone	Superdisintegrant
Hypromellose	Film-coating polymer and possibly binder
Magnesium stearate	Lubricant
Titanium dioxide	Opacifier and color-control agent in the coating
Talc	Anti-tacking and coating aid
Polyethylene glycol	Plasticizer in the film coat
Iron oxides	Tablet-strength colorants

Effient is supplied in 5 mg and 10 mg strengths. The tablets are immediate release and film coated. The 5 mg strength is beige, while the 10 mg strength is pink.[1]

The formulation uses a standard balance between manufacturability and rapid disintegration. Microcrystalline cellulose supports compactability and mechanical strength. Crospovidone promotes tablet breakup after ingestion. Magnesium stearate reduces tooling friction, but excessive lubrication can slow wetting and dissolution. Lactose anhydrous increases tablet mass without adding substantial water during processing.

Why does the Effient excipient combination matter?

The excipient strategy addresses four technical requirements: low-dose uniformity, rapid drug release, mechanical integrity and scalable production.

Low-dose content uniformity

Prasugrel is present at a low dose relative to the total tablet mass. The 5 mg tablet creates a greater content-uniformity challenge than the 10 mg tablet because small distribution differences represent a larger percentage of the labeled dose.

A manufacturer using the same excipient architecture would need to control:

• Active pharmaceutical ingredient particle-size distribution
• Blend segregation
• Mixing time and order of addition
• Powder-flow behavior
• Sampling strategy
• Compression-force variation
• Tablet weight variation

Microcrystalline cellulose and lactose can provide a relatively large carrier phase for distributing a low-dose active ingredient. The formulation is therefore compatible with conventional direct-compression or dry-granulation development, subject to the specific process selected by the manufacturer.

Immediate-release performance

Crospovidone is the principal disintegration-oriented excipient identified in the label. It provides rapid tablet breakup through wicking and swelling-related mechanisms. Its performance can be affected by compression force, lubricant concentration, particle size and the hydrophobicity of the blend.

A generic developer should not assume that matching the labeled excipients will automatically reproduce Effient dissolution. Dissolution depends on grade, supplier, particle morphology, manufacturing process, tablet hardness, coating weight and storage conditions.

Film-coat differentiation

The film coat has limited therapeutic functionality but provides commercial and operational value. It supports:

• Product identification by strength
• Improved tablet handling
• Reduced dusting
• Improved patient acceptability
• Color-based prevention of strength confusion
• Protection from routine handling and environmental exposure

A generic company can usually select an equivalent color system and coating technology, but it must manage color matching, visual inspection, coating uniformity and potential regulatory requirements for colorants in each jurisdiction.

Manufacturing robustness

Lactose anhydrous and microcrystalline cellulose are widely available excipients with established pharmaceutical use. This reduces supply-chain complexity compared with formulations that depend on proprietary polymers, lipid systems, hot-melt carriers or specialized capsule technologies.

The main manufacturing risks are blend uniformity, over-lubrication, tablet capping, coating defects and dissolution drift. These risks are manageable with standard process-development tools, including design of experiments, powder rheology, near-infrared blend monitoring and in-process tablet testing.

What formulation opportunities exist around Effient?

The strongest opportunities involve incremental improvement rather than replication of the original tablet.

Lactose-free prasugrel tablets

Effient contains lactose anhydrous.[1] A lactose-free product could replace lactose with one or more alternatives such as mannitol, dibasic calcium phosphate, pregelatinized starch or an alternative grade of microcrystalline cellulose.

Potential commercial benefits include:

• Broader use in patients who avoid lactose-containing medicines
• Differentiation in hospital formularies
• Simplified positioning for patients with excipient sensitivities
• A potential 505(b)(2) or line-extension strategy, depending on the product and regulatory pathway

The regulatory value of a lactose-free formulation is strongest if the product offers a clearly documented clinical or usability benefit. A simple excipient substitution may otherwise compete primarily on price.

Modified-release and chronotherapy concepts

Prasugrel is used for platelet inhibition in acute coronary syndrome and after PCI. A modified-release formulation could seek to alter exposure, reduce peak-related adverse effects or improve adherence. The commercial case is weak unless pharmacokinetic or clinical data demonstrate a meaningful benefit.

A modified-release product would face greater regulatory and development risk than an immediate-release generic. It could also create a new patent estate around release control, polymer selection, multiparticulates, coating layers or manufacturing methods.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with swallowing difficulties, emergency-care administration or post-procedure use. The formulation would need to address:

• Taste masking
• Rapid disintegration
• Mechanical friability
• Dose uniformity
• Moisture sensitivity
• Packaging in high-barrier blisters

Prasugrel's low dose is technically favorable for an orally disintegrating tablet. The antiplatelet indication may support hospital and acute-care positioning, but clinical workflow and reimbursement would determine adoption.

Sprinkle, dispersible or liquid presentations

A dispersible or liquid formulation could support patients unable to swallow conventional tablets. Such a product would need robust stability data, dose-measurement controls and compatibility with enteral administration if that is part of the intended use.

The main commercial challenge is that prasugrel is often administered in controlled clinical settings or to patients who can take standard tablets. A liquid or dispersible product therefore requires a defined institutional or patient population rather than broad consumer demand.

Fixed-dose combinations

A prasugrel combination with aspirin could reduce pill burden for selected patients. The concept has potential formulation and commercial value, but it creates clinical and regulatory complications:

• Aspirin dosing may vary by patient and indication
• Bleeding risk requires careful labeling
• Dose flexibility is reduced
• Prescribers may prefer separate titration or discontinuation
• Combination products may be restricted by guideline and hospital protocols

A fixed-dose combination would be more defensible if it targets a specific treatment duration, care pathway or adherence problem.

What patents protect Effient and its formulation?

Effient's original exclusivity was primarily associated with prasugrel as an active pharmaceutical ingredient and its approved use, not with an unusually complex excipient system. The FDA Orange Book identifies patents and regulatory exclusivities associated with approved products, but current patent status must be assessed by product number, listed patent, expiration adjustment and any applicable pediatric extension.[2]

The label alone does not establish that the specific excipient combination remains protected. Excipients listed in an FDA label are not, by themselves, evidence of a live formulation patent.

Relevant patent categories include:

Patent category	Relevance to prasugrel products
Active-ingredient patents	Protect prasugrel or a related chemical form
Salt or crystalline-form patents	May cover prasugrel hydrochloride or solid-state properties
Formulation patents	May cover excipient ratios, dissolution, stability or dosage forms
Method-of-use patents	May cover treatment populations or dosing regimens
Manufacturing patents	May cover crystallization, purification or tablet production
Packaging patents	May cover moisture protection or unit-dose presentation

For an ANDA developer, the central question is whether any unexpired Orange Book-listed patents require a Paragraph IV certification. A generic sponsor must separately evaluate non-Orange-Book patents, regulatory exclusivity, patent litigation history and freedom to operate in each market.[2,3]

When did Effient lose regulatory exclusivity?

Effient was approved by the FDA in July 2009.[4] As a new chemical entity, it received five years of NCE exclusivity, subject to the statutory framework then in effect. Pediatric exclusivity can add six months when granted after completion of qualifying FDA requirements.[3]

The practical U.S. generic-entry analysis depends on more than the original NCE period. It requires review of:

1. FDA approval and exclusivity records
2. Orange Book patent listings
3. Patent expiration and term adjustment
4. ANDA certifications
5. Paragraph IV litigation
6. Any 30-month stay
7. Settlement agreements
8. Commercial launch agreements

Prasugrel is no longer protected by an active new-chemical-entity exclusivity period. The remaining competitive barriers are mainly patent, regulatory, manufacturing, contracting and market-access issues.

What is the Orange Book status of Effient?

Effient is an FDA-approved prescription drug listed in the Orange Book under prasugrel hydrochloride tablets.[2] The Orange Book is the operative U.S. source for identifying therapeutic-equivalence evaluations, listed patents and approved dosage forms.

For commercial diligence, the relevant questions are:

• Which Effient product numbers remain listed?
• Are 5 mg and 10 mg tablets separately covered?
• Which patents are listed against each strength?
• Are any patents expired, delisted or subject to a statutory stay?
• Have FDA-approved ANDAs received therapeutic-equivalence ratings?
• Are generic products currently marketed or only approved?

An Orange Book review should be performed at the product level. A patent listed against one strength or dosage form may not apply identically to another.

Which companies are challenging Effient?

Public generic competition should be assessed through FDA approval records, Orange Book therapeutic-equivalence data and commercial availability. An approved ANDA does not always result in an immediate commercial launch. Companies may delay launch because of price erosion, manufacturing constraints, litigation settlements, supply agreements or limited market size.

The relevant competitive groups include:

• Large generic manufacturers with established cardiovascular portfolios
• Regional suppliers serving hospital systems
• Contract manufacturers with prasugrel capability
• Specialty companies developing differentiated oral dosage forms
• API suppliers seeking vertical integration

Biosimilar risk is not relevant to Effient because prasugrel is a small-molecule drug, not a biologic. Competition will come from chemically equivalent generics, authorized-generic structures and differentiated reformulations.

What commercial opportunities exist for Effient excipients?

The highest-probability opportunities are in cost reduction and supply resilience.

Excipient substitution

A developer can evaluate alternate suppliers and grades for lactose, microcrystalline cellulose, crospovidone, hypromellose and magnesium stearate. The commercial value comes from:

• Dual sourcing
• Lower material cost
• Reduced lead times
• Better compressibility
• Lower rejection rates
• Improved tablet throughput

Any substitution requires comparative quality and dissolution work. FDA's Inactive Ingredient Database can support precedent analysis, but database presence does not eliminate the need for product-specific qualification.[5]

Direct-compression optimization

Effient's excipients are compatible with a conventional solid-dose platform. A manufacturer may improve economics through direct compression if blend flow, segregation control and content uniformity are adequate. Direct compression can reduce granulation steps, solvent use, drying time and equipment requirements.

The principal risk is low-dose segregation. A formulation with strong flow but weak active distribution can fail content-uniformity requirements even when tablets meet weight and hardness specifications.

Hospital unit-dose packaging

Prasugrel is used in cardiovascular hospital pathways, including PCI-related treatment. Unit-dose blister packaging can support medication administration, inventory control and product identification.

Commercial differentiation may include:

• 5 mg and 10 mg strength separation
• Barcode-enabled hospital packaging
• Calendar or course-based packaging
• High-barrier materials for humidity protection
• Institutional bulk packs
• Automated dispensing cabinet compatibility

Packaging is a commercial extension of the excipient strategy because moisture and handling can affect tablet performance, particularly when the formulation uses conventional water-soluble and polymeric components.

Pediatric and geriatric usability

Prasugrel use is clinically constrained by indication, age, weight and bleeding risk. A pediatric formulation opportunity would require a clear clinical basis and FDA support. A geriatric-oriented product could focus on swallowing, tablet size, packaging and administration rather than changing the active dose.

An orally disintegrating or smaller-format tablet may have more realistic commercial value than a pediatric product, provided the target population is clinically defined.

How strong is the Effient formulation patent estate?

The formulation estate appears easier to design around than a delivery platform based on proprietary polymers, nanoparticles or device integration. A conventional excipient list creates a relatively broad manufacturing opportunity, but patent strength cannot be assessed from the inactive-ingredient disclosure alone.

The strongest potential formulation claims would generally require limitations involving:

• Specific excipient ratios
• Narrow dissolution profiles
• Defined impurity limits
• Solid-state characteristics
• Moisture or stability performance
• Manufacturing parameters
• Particular dosage forms

A competitor can reduce infringement risk by changing excipient grades, ratios, processing conditions, coating composition or dosage-form architecture while preserving bioequivalence and product quality.

What generic launch risks exist for prasugrel?

A generic prasugrel launch faces five principal risks.

Regulatory risk

The sponsor must demonstrate pharmaceutical equivalence and bioequivalence and comply with current FDA product-specific expectations. Formulation changes can affect dissolution, exposure and tablet performance.[3]

Clinical-label risk

Prasugrel carries important safety restrictions and warnings related to bleeding. Generic labeling must remain consistent with the reference product unless FDA authorizes a difference.

Manufacturing risk

Low-dose blend uniformity, tablet strength, dissolution and coating consistency are central critical-quality attributes.

Market risk

Generic prices can decline rapidly after multiple entrants. A differentiated excipient profile is unlikely to preserve a premium without a clear patient or institutional benefit.

Supply-chain risk

Prasugrel API availability, qualified excipient suppliers and high-barrier packaging can determine whether a company can maintain reliable supply after launch.

How does Effient compare with competing antiplatelet products?

Effient competes primarily with Plavix, which contains clopidogrel, and Brilinta, which contains ticagrelor. The excipient opportunity differs across these products because the active ingredients have different physicochemical and clinical profiles.

Product	Active ingredient	Dosage form	Excipient opportunity
Effient	Prasugrel hydrochloride	Immediate-release film-coated tablet	Generic substitution, lactose-free version, ODT or hospital packaging
Plavix	Clopidogrel bisulfate	Immediate-release film-coated tablet	High-volume generic manufacturing and combination products
Brilinta	Ticagrelor	Immediate-release tablet	Formulation differentiation, adherence and dose-management opportunities

Effient has a low-dose tablet profile that may facilitate alternate dosage forms. Brilinta and clopidogrel have larger established generic or branded competitive ecosystems, which can make market entry more price-sensitive.

What licensing and partnership opportunities exist?

Potential licensing structures include:

• Prasugrel API supply agreements
• Regional generic commercialization rights
• Co-development of lactose-free or orally disintegrating tablets
• Hospital-packaging partnerships
• Contract manufacturing and technology-transfer arrangements
• Authorized-generic supply agreements
• Formulation patent licenses

The most valuable assets are likely to be regulatory-ready products, reliable API supply, demonstrated bioequivalence and commercial access to hospital systems. An excipient substitution alone is unlikely to command a substantial license unless it produces a measurable stability, manufacturing or usability advantage.

Key Takeaways

• Effient uses a conventional immediate-release tablet platform based on lactose anhydrous, microcrystalline cellulose, crospovidone, hypromellose and magnesium stearate.
• The formulation is designed for low-dose content uniformity, rapid disintegration, mechanical strength and scalable production.
• The largest excipient opportunities are lactose-free substitution, direct-compression optimization, orally disintegrating tablets and hospital unit-dose packaging.
• Effient is a small-molecule drug, so biosimilar competition does not apply.
• Generic entry depends on current Orange Book listings, patent certifications, litigation, regulatory status and commercial launch economics.
• The excipient disclosure does not, by itself, establish a live formulation patent barrier.
• A differentiated prasugrel product needs a measurable advantage in usability, stability, manufacturing cost or institutional workflow to support pricing above a standard generic.

FAQs

Can a generic prasugrel product use different excipients from Effient?

Yes. A generic product may use different inactive ingredients if it meets applicable pharmaceutical-equivalence, bioequivalence, quality and labeling requirements. The formulation must preserve critical performance attributes, including dissolution and content uniformity.[3]

Is lactose in Effient a commercial weakness?

It can create a differentiation opportunity, but lactose content alone is unlikely to support a premium product. A lactose-free prasugrel tablet would need a defined target population, supply advantage or usability benefit.

Could prasugrel be developed as an orally disintegrating tablet?

Yes, technically. Its low dose is compatible with an orally disintegrating format. Development would require taste masking, rapid disintegration, moisture protection, dose uniformity and a commercially credible clinical-use case.

Are Effient excipients protected by patents?

The label does not establish patent protection. Patent coverage must be assessed through issued patent claims, Orange Book listings, prosecution histories, patent-term calculations and relevant non-Orange-Book rights.

Is a prasugrel fixed-dose combination with aspirin commercially attractive?

It may reduce pill burden, but dose flexibility, bleeding-risk management and prescriber preference for separate products limit the opportunity. The strongest case would involve a clearly defined treatment pathway and adherence benefit.

References

1. U.S. Food and Drug Administration. (2024). Effient (prasugrel hydrochloride) tablets: Prescribing information. Daiichi Sankyo, Inc., and Eli Lilly and Company.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2013). ANDA submissions: Content and format of abbreviated new drug applications. FDA.

4. U.S. Food and Drug Administration. (2009). FDA approves Effient to reduce the risk of blood clots in patients undergoing angioplasty. FDA.

5. U.S. Food and Drug Administration. (2025). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm